Comparison of Proton Magnetic Resonance Spectroscopy with Fluorine-18 2-Fluoro-Deoxyglucose Positron Emission Tomography for Assessment of Brain Tumor Progression

Journal of Neuroimaging

Volumn 22, Issue 2, 2012, Pages 184-190

  Imani, Farzin ^a   Boada, Fernando E ^a   Lieberman, Frank S ^a   Davis, Denise K ^a   Deeb, Erin L ^a   Mountz, James M ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

FDG PET; Glioma; Magnetic resonance spectroscopy; MRS; Positron emission tomography

Indexed keywords

CHOLINE; CREATINE; FLUORINE 18; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GLIOMA; HISTOLOGY; HUMAN; INTERMETHOD COMPARISON; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; STEREOTACTIC RADIOSURGERY; SYMPTOM; TUMOR GROWTH;

ADULT; AGED; BRAIN; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOMA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY;

EID: 84859715402     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/j.1552-6569.2010.00561.x     Document Type: Article

References (49)

1. CBTRUS. Central Brain Tumor Registry of the United States Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2006, 2010.
2. Kleihues P, Cavenee WK; International Agency for Research on Cancer. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press, 2000.
3. Kelly PJ, Daumas-Duport C, Scheithauer BW, et al. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987;62(6):450-459.
4. Earnest Ft, Kelly PJ, Scheithauer BW, et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 1988;166(3):823-827.
5. Buckner JC, Brown PD, O'Neill BP, et al. Central nervous system tumors. Mayo Clin Proc 2007;82(10):1271-1286.
6. Danielsen ER, Ross B. Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases. CRC Press, 1999.
7. Michaelis T, Merboldt KD, Bruhn H, et al. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology 1993;187(1):219-227.
8. Herminghaus S, Pilatus U, Moller-Hartmann W, et al. Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed 2002;15(6):385-392.
9. Tewson TJ, Welch MJ, Raichle ME. [18F]-labeled 3-deoxy-3-fluoro-d-glucose: synthesis and preliminary biodistribution data. J Nucl Med 1978;19(12):1339-1345.
10. Senft C, Hattingen E, Pilatus U, et al. Diagnostic value of proton magnetic resonance spectroscopy in the noninvasive grading of solid gliomas: comparison of maximum and mean choline values. Neurosurgery 2009;65(5):908-913; discussion 913.
11. Fayed N, Davila J, Medrano J, et al. Malignancy assessment of brain tumours with magnetic resonance spectroscopy and dynamic susceptibility contrast MRI. Eur J Radiol 2008;67(3):427-433.
12. Zonari P, Baraldi P, Crisi G. Multimodal MRI in the characterization of glial neoplasms: the combined role of single-voxel MR spectroscopy, diffusion imaging and echo-planar perfusion imaging. Neuroradiology 2007;49(10):795-803.
13. Zeng QS, Li CF, Zhang K, et al. Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury. J Neurooncol 2007;84(1):63-69.
14. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24(10):1989-1998.
15. Reijneveld JC, Van Der Grond J, Ramos LM, et al. Proton MRS imaging in the follow-up of patients with suspected low-grade gliomas. Neuroradiology 2005;47(12):887-891.
16. Lichy MP, Plathow C, Schulz-Ertner D, et al. Follow-up gliomas after radiotherapy: 1H MR spectroscopic imaging for increasing diagnostic accuracy. Neuroradiology 2005;47(11):826-834.
17. Floeth FW, Pauleit D, Wittsack HJ, et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-l-tyrosine and magnetic resonance spectroscopy. J Neurosurg 2005;102(2):318-327.
18. Fayed N, Modrego PJ. The contribution of magnetic resonance spectroscopy and echoplanar perfusion-weighted MRI in the initial assessment of brain tumours. J Neurooncol. 2005;72(3):261-265.
19. Plotkin M, Eisenacher J, Bruhn H, et al. 123I-IMT SPECT and 1H MR-spectroscopy at 3.0 T in the differential diagnosis of recurrent or residual gliomas: a comparative study. J Neurooncol 2004;70(1):49-58.
20. McKnight TR, von dem Bussche MH, Vigneron DB, et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002;97(4):794-802.
21. Patronas NJ, Di Chiro G, Brooks RA, et al. Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 1982;144(4):885-889.
22. Doyle WK, Budinger TF, Valk PE, et al. Differentiation of cerebral radiation necrosis from tumor recurrence by [18F]FDG and 82Rb positron emission tomography. J Comput Assist Tomogr 1987;11(4):563-570.
23. Di Chiro G, Oldfield E, Wright DC, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol 1988;150(1):189-197.
24. Valk PE, Budinger TF, Levin VA, et al. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg 1988;69(6):830-838.
25. Kim EE, Chung SK, Haynie TP, et al. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. Radiographics 1992;12(2):269-279.
26. Janus TJ, Kim EE, Tilbury R, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993;33(5):540-548.
27. Kahn D, Follett KA, Bushnell DL, et al. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET. AJR Am J Roentgenol 1994;163(6):1459-1465.
28. Ricci PE, Karis JP, Heiserman JE, et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR Am J Neuroradiol 1998;19(3):407-413.
29. Van Laere K, Ceyssens S, Van Calenbergh F, et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 2005;32(1):39-51.
30. Wang SX, Boethius J, Ericson K. FDG-PET on irradiated brain tumor: ten years' summary. Acta Radiol 2006;47(1):85-90.
31. Alger JR, Frank JA, Bizzi A, et al. Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET. Radiology 1990;177(3):633-641.
32. Prat R, Galeano I, Lucas A, et al. Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-((18)F) fluoro-2-deoxy-d-glucose positron emission tomography for detection of recurrence or grade increase in gliomas. J Clin Neurosci 2010;17(1):50-53.
33. Chao ST, Suh JH, Raja S, et al. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001;96(3):191-197.
34. Castillo M, Kwock L, Mukherji SK. Clinical applications of proton MR spectroscopy. AJNR Am J Neuroradiol 1996;17(1):1-15.
35. Weinhard K. Applications of 3D PET. In: Bendriem B, Townsend DW, eds. The Theory and Practice of 3D PET. Dordrecht; Boston: Kluwer Academic, 1998:133-167.
36. Watson CC. New, faster, image-based scatter correction for 3D PET. Nucl Sci, IEEE Trans 2000;47(4):1587-1594.
37. Padma MV, Said S, Jacobs M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003;64(3):227-237.
38. Meyer PT, Schreckenberger M, Spetzger U, et al. Comparison of visual and ROI-based brain tumour grading using 18F-FDG PET: ROC analyses. Eur J Nucl Med 2001;28(2):165-174.
39. Julious SA. Two-sided confidence intervals for the single proportion: comparison of seven methods by Robert G. Newcombe, Statistics in Medicine 1998;17:857-872. Stat Med 2005;24(21):3383-3384.
40. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17(8):857-872.
41. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927;22(158):209-212.
42. Vollset SE. Confidence intervals for a binomial proportion. Stat Med 1993;12(9):809-824.
43. Olivero WC, Dulebohn SC, Lister JR. The use of PET in evaluating patients with primary brain tumours: is it useful? J Neurol Neurosurg Psychiatry 1995;58(2):250-252.
44. Burger PC, Mahley MS, Jr., Dudka L, et al. The morphologic effects of radiation administered therapeutically for intracranial gliomas: a postmortem study of 25 cases. Cancer 1979;44(4):1256-1272.
45. Marks JE, Baglan RJ, Prassad SC, et al. Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. Int J Radiat Oncol Biol Phys 1981;7(2):243-252.
46. Kreis R, Ernst T, Ross BD. Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn Reson Med 1993;30(4):424-437.
47. Miller BL. A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed 1991;4(2):47-52.
48. Castillo M, Kwock L, Scatliff J, et al. Proton MR spectroscopy in neoplastic and non-neoplastic brain disorders. Magn Reson Imaging Clin N Am 1998;6(1):1-20.
49. Warburg O. On the origin of cancer cells. Science 1956;123(3191):309-314.